Literature DB >> 19590199

Asymmetric dimethylarginine impairs glucose utilization via ROS/TLR4 pathway in adipocytes: an effect prevented by vitamin E.

Zhi-Chun Yang1, Kuan-Song Wang, Yan Wu, Xiao-Qing Zou, Yue-Yun Xiang, Xiao-Ping Chen, Yuan-Jian Li.   

Abstract

BACKGROUND: Asymmetric dimethylarginine (ADMA), the inhibitor of nitric oxide synthase (NOS), has been reported to be associated with glucose metabolism, but its mechanisms remain unknown.
METHODS: In 3T3-L1 adipocytes, we measured the effects of ADMA on glucose transport process under basal or insulin-induced condition, and examined the production of nitric oxide (NO), reactive oxygen species (ROS) and tumor necrosis factor alpha (TNF-alpha), and the expression of toll-like receptor 4 (TLR4).
RESULTS: ADMA significantly impaired basal or insulin-stimulated 2-deoxy- [3H] glucose uptake, and decreased the expression of insulin receptor substrate-1 (IRS-1) and glucose transporter-4 (GLUT4). Phosphorylated protein of IRS-1 and translocation of GLUT4 with insulin-stimulation were also inhibited by ADMA. NO decreased, while production of ROS and TNF-alpha, and expression of TLR4 increased after ADMA treatment. Vitamin E reduced the effects of ADMA on glucose transport system, and on NO, ROS and TLR4. Moreover, vitamin E decreased ADMA contents by up-regulating dimethylarginine dimethylaminohydrolase (DDAH) activity in adipocytes. Though L-arginine also increased NO level, but failed to reduce the effects of ADMA.
CONCLUSION: ADMA significantly impairs both basal and insulin-stimulated glucose transport in adipocytes, which may relate to activation of the ROS/TLR4 pathway. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590199     DOI: 10.1159/000227819

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  8 in total

1.  Accelerated fat cell aging links oxidative stress and insulin resistance in adipocytes.

Authors:  Finny Monickaraj; Sankaramoorthy Aravind; Pichamoorthy Nandhini; Paramasivam Prabu; Chandrakumar Sathishkumar; Viswanathan Mohan; Muthuswamy Balasubramanyam
Journal:  J Biosci       Date:  2013-03       Impact factor: 1.826

Review 2.  Toll-like Receptors in the Vascular System: Sensing the Dangers Within.

Authors:  Styliani Goulopoulou; Cameron G McCarthy; R Clinton Webb
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

3.  The ADMA-Metformin Hypothesis: Linking the Cardiovascular Consequences of the Metabolic Syndrome and Type 2 Diabetes.

Authors:  William H Bestermann
Journal:  Cardiorenal Med       Date:  2011-10-04       Impact factor: 2.041

Review 4.  Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension?

Authors:  Kenia Pedrosa Nunes; Amanda Almeida de Oliveira; Francesca Elisabeth Mowry; Vinicia Campana Biancardi
Journal:  Br J Pharmacol       Date:  2018-08-09       Impact factor: 8.739

5.  Antrodia camphorata polysaccharide improves inflammatory response in liver injury via the ROS/TLR4/NF-κB signal.

Authors:  Yi Yang; Chenyang Han; Yongjia Sheng; Jin Wang; Wenyan Li; Xiaohong Zhou; Shuiliang Ruan
Journal:  J Cell Mol Med       Date:  2022-03-29       Impact factor: 5.295

Review 6.  Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension.

Authors:  Cameron G McCarthy; Styliani Goulopoulou; Camilla F Wenceslau; Kathryn Spitler; Takayuki Matsumoto; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-25       Impact factor: 4.733

Review 7.  Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance.

Authors:  Arnold N Onyango
Journal:  Oxid Med Cell Longev       Date:  2018-07-09       Impact factor: 6.543

8.  Impact of 3-Amino-1,2,4-Triazole (3-AT)-Derived Increase in Hydrogen Peroxide Levels on Inflammation and Metabolism in Human Differentiated Adipocytes.

Authors:  Francisco Javier Ruiz-Ojeda; Carolina Gomez-Llorente; Concepción María Aguilera; Angel Gil; Azahara Iris Rupérez
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.